EuroapiFRA:940 +0.96%54 EBIT per Share is €-1.38 as of Dec. 2025. GuruFocus rates FRA:940 with a GF Score™ of 54/100 and a GF Value™ of €2.91 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 810 Drug Manufacturers companies, Euroapi ranks worse than 97.04% on this metric.
Euroapi's EBIT per Share for the
six
months ended in Dec. 2025 was €-1.10.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.38.
During the past 3 years, the average EBIT per Share Growth Rate was -60.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Euroapi's EBIT per Share or its related term are showing as below:
FRA:940'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -60.2 Med: -60.2 Max: -60.2
Current: -60.2
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Euroapi was -60.20% per year. The lowest was -60.20% per year. And the median was -60.20% per year.
FRA:940's 3-Year EBIT Growth Rate is ranked worse than 97.04% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs FRA:940: -60.20
Euroapi's EBIT for the
six
months ended in Dec. 2025 was €-104.0 Mil.
Euroapi (FRA:940) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Euroapi EBIT per Share Related Terms
Euroapi EBIT per Share Historical Data
* Premium members only.
The historical data trend for Euroapi's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Euroapi (FRA:940) has a EBIT per Share of €-1.38 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Euroapi and its competitors. According to the industry distribution chart, Euroapi ranks #786 out of 810 companies in the Drug Manufacturers industry, placing it in the top 97%.
Is Euroapi's EBIT per Share too high?
Euroapi's current EBIT per Share is €-1.38. Based on the distribution chart, Euroapi ranks #786 out of 810 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Euroapi has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Euroapi's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euroapi ranks #786 out of 810 companies for EBIT per Share. This places Euroapi in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Euroapi and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euroapi's current EBIT per Share is €-1.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euroapi stock overvalued right now?
Based on GuruFocus' analysis, Euroapi (FRA:940) is currently considered Possible Value Trap. The stock's GF Value™ is €2.91, compared to a current price of €1.27 — trading 56.5% below its estimated fair value. The current EBIT per Share is €-1.38. Euroapi's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Euroapi (FRA:940), the current EBIT per Share is €-1.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euroapi (FRA:940) Overvalued in 2026?
Based on GuruFocus' analysis, Euroapi stock appears to be undervalued.
The current stock price of €1.27 is trading 56.5% below its estimated GF Value™ of €2.91.
GuruFocus considers Euroapi to be Possible Value Trap.
Key valuation signals for FRA:940:
EBIT per Share: €-1.38
GF Value™: €2.91 vs. price of €1.27 (56.5% below fair value)
No single metric tells the full story. See the FRA:940 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates, analgesics, and others. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers.
54GF Score
Get the complete analysis for FRA:940
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:940 has been successfully added to your 
